CompletedNot Applicable

Identification of Biomarkers in Spinocerebellar Ataxia 3

United States22 participantsStarted 2019-02-21

Plain-language summary

The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: •Confirmed Genetic Testing of SCA3 or Healthy Volunteers Exclusion Criteria: * People with: * unstable thyroid * unstable intestinal/stomach issues * unstable heart issues * unstable liver issues * unstable kidney issues * unstable lung issues * unstable hormone issues * unstable mental disorders at screening * a tumor or evidence of having a tumor * a chronic infection or any severe acute infection within 3 months prior to screening * People who: * Take anti-coagulants and NSAIDs * Have started any investigational medications in the last month * Women who are pregnant or breast feeding

What they're measuring

Change in Ataxin 3 Levels in Cerebrospinal Fluid Specimens

Timeframe: 4 Hours

Change in Ataxin 3 Levels in Blood Plasma Specimens

Timeframe: 4 Hours

Trial details

NCT IDNCT03885167

SponsorUniversity of Michigan

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-04

View on ClinicalTrials.gov More Spinocerebellar Ataxia Type 3 trials